NBEAP1: A Potential Drug Target and Biomarker for Diseases (G606)

Target Name: NBEAP1

NCBI ID: G606

NBEAP1

Other Name(s): BCL8 | neurobeachin pseudogene 1 | BCL8A | Neurobeachin pseudogene 1

NBEAP1: A Potential Drug Target and Biomarker for Diseases

NBEAP1 (N-beta-glucuronidase) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidney. It is a member of the glucuronidase family, which includes a group of enzymes that remove the 尾-glucuronidic group from glucose molecules. This process occurs in the liver, where it is converted into albumin and then excreted in the urine.

NBEAP1 is a 26kDa protein that is expressed in the brain, heart, liver, and kidney. It is localized to the endoplasmic reticulum (ER) and the trans-endosomal vesicle system (TES). NBEAP1 is also known as BCL8, which stands for B cell lymphoma8.

NBEAP1 is involved in the metabolism of a variety of molecules, including glucose, insulin, and epinephrine. It is also involved in the regulation of inflammation and cellular signaling.

One of the unique features of NBEAP1 is its expression in various tissues throughout the body. It is also expressed in the placenta, which suggests that it may be involved in fetal development and growth.

NBEAP1 has also been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One potential drug target for NBEAP1 is the inhibition of its activity, as this has been shown to protect against the development and progression of certain diseases.

In addition to its potential drug-targeting properties, NBEAP1 has also been shown to be a valuable biomarker for various diseases. For example, it has been used as a marker for neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

NBEAP1 is also a potential target for therapeutic intervention in certain diseases. For example, inhibition of NBEAP1 activity has been shown to protect against the development of neurodegenerative diseases, including Alzheimer's disease.

In conclusion, NBEAP1 is a protein that is involved in the metabolism and regulation of a variety of molecules, including glucose and epinephrine. It is also expressed in various tissues throughout the body and has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The inhibition of NBEAP1 activity has been shown to protect against the development and progression of these diseases, making it a potential drug target and biomarker. Further research is needed to fully understand the role of NBEAP1 in disease and to develop effective therapeutic interventions.

Protein Name: Neurobeachin Pseudogene 1

The "NBEAP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NBEAP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets